ICMR and Panacea Biotec initiates Phase III clinical trial of DengiAll
The clinical trial will be conducted at 19 sites with 10,335 participants across India
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The partnership marks a significant milestone in integrating digital health education into medical curricula
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
Morepen Labs successfully raised Rs. 200 Crore through QIP
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The inspection was concluded with zero observations
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Subscribe To Our Newsletter & Stay Updated